首页> 外文期刊>European Journal of Pharmacology: An International Journal >Bis-N-norgliovictin, a small-molecule compound from marine fungus, inhibits LPS-induced inflammation in macrophages and improves survival in sepsis
【24h】

Bis-N-norgliovictin, a small-molecule compound from marine fungus, inhibits LPS-induced inflammation in macrophages and improves survival in sepsis

机译:Bis-N-norgliovictin,一种来自海洋真菌的小分子化合物,可抑制LPS诱导的巨噬细胞炎症并提高败血症生存率

获取原文
获取原文并翻译 | 示例
           

摘要

Sepsis is a highly lethal disorder characterized by systemic inflammation, and Toll-like receptor 4 (TLR4) in macrophages plays a crucial role in modulating innate immune response and outcome of sepsis. During the screening of natural products against inflammation, we identified bis-N-norgliovictin, a small-molecule compound isolated from marine-derived fungus, significantly inhibited lipopolysaccharide (LPS, ligand of TLR4)-induced tumor necrosis factor-α (TNF-α) production in RAW264.7 cells. In this study, we evaluated the effect of bis-N-norgliovictin on TLR4-mediated inflammation in mouse macrophages and LPS-induced sepsis model. In RAW264.7 and mouse peritoneal macrophages, bis-N-norgliovictin dose-dependently inhibited LPS-induced production of TNF-α, interleukin-6 (IL-6), interferon-β (IFN-β) and monocyte chemoattractant protein (MCP-1), but without suppressing cell viability. The anti-inflammatory effect was attributed to the down-regulation of TLR4-triggered myeloid differentiation primary response protein 88 (MyD88)-dependent and TIR-containing adapter inducing interferon-β (TRIF)-dependent signaling pathways, including p38 and c-Jun N-terminal kinase (JNK) of mitogen-activated protein kinases (MAPKs), nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3) cascades. Importantly, bis-N-norgliovictin also protected mice against LPS-induced endotoxic shock. Intravenous injection of bis-N-norgliovictin 1 h before LPS challenge dose-dependently inhibited LPS-induced increases in serum levels of TNF-α, IL-6, MCP-1 and IL-10, attenuated liver and lung injury and diminished M1 macrophage polarization in liver. Our results demonstrate that bis-N-norgliovictin exhibit potent anti-inflammatory effect both in vitro and in vivo. These findings suggest that bis-N-norgliovictin can be a useful therapeutic candidate for the treatment of sepsis and other inflammatory diseases.
机译:败血症是一种高度致死性疾病,其特征在于全身性炎症,巨噬细胞中的Toll样受体4(TLR4)在调节先天性免疫应答和败血症的结果中起着至关重要的作用。在针对炎症的天然产物筛选过程中,我们确定了bis-N-norgliovictin,这是一种从海洋真菌中分离的小分子化合物,可显着抑制脂多糖(LPS,TLR4的配体)诱导的肿瘤坏死因子-α(TNF-α) )在RAW264.7细胞中产生。在这项研究中,我们评估了bis-N-norgliovictin对TLR4介导的小鼠巨噬细胞和LPS诱导的脓毒症模型炎症的影响。在RAW264.7和小鼠腹膜巨噬细胞中,bis-N-降血糖素剂量依赖性地抑制LPS诱导的TNF-α,白介素-6(IL-6),干扰素-β(IFN-β)和单核细胞趋化蛋白(MCP)的产生-1),但不抑制细胞活力。该抗炎作用归因于TLR4触发的髓样分化初级反应蛋白88(MyD88)依赖性和含TIR的衔接子诱导干扰素-β(TRIF)依赖性信号传导途径的下调,包括p38和c-Jun丝裂原活化蛋白激酶(MAPK),核因子-κB(NF-κB)和干扰素调节因子3(IRF3)的N端激酶(JNK)级联。重要的是,bis-N-norgliovictin还可以保护小鼠免受LPS诱导的内毒素性休克。在LPS攻击前1小时静脉注射bis-N-norgliovictin剂量依赖性地抑制LPS诱导的血清TNF-α,IL-6,MCP-1和IL-10水平的升高,减轻肝和肺损伤并减轻M1巨噬细胞肝脏极化。我们的结果表明,bis-N-norgliovictin在体外和体内均表现出强大的抗炎作用。这些发现表明,bis-N-降血糖素可以作为败血症和其他炎性疾病的有用治疗候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号